Abstract
To date, four genome-wide association studies (GWAS) of obsessive-compulsive disorder (OCD) have been published, reporting a high single-nucleotide polymorphism (SNP)-heritability of 28% but finding only one significant SNP. A sub-stantial increase in sample size will likely lead to further identification of SNPs, genes, and biological pathways mediating the susceptibility to OCD. We conducted a GWAS meta-analysis with a 2-3-fold increase in case sample size (OCD cases: N = 37,015, controls: N = 948,616) compared to the last OCD GWAS, including six previously published cohorts (OCGAS, IOCDF-GC, IOCDF-GC-trio, NORDiC-nor, NORDiC-swe, and iPSYCH) and unpublished self-report data from 23andMe Inc. We explored the genetic architecture of OCD by conducting gene-based tests, tissue and celltype enrichment analyses, and estimating heritability and genetic correlations with 74 pheno-types. To examine a potential heterogeneity in our data, we conducted multivariable GWASs with MTAG. We found support for 15 independent genome-wide significant loci (14 new) and 79 protein-coding genes. Tissue enrichment analyses implicate multiple cortical regions, the amygdala, and hypothalamus, while cell type analyses yielded 12 cell types linked to OCD (all neurons). The SNP-based heritability of OCD was estimated to be 0.08. Using MTAG we found evidence for specific genetic underpinnings characteristic of different cohort-ascertainment and identified additional significant SNPs. OCD was genetically correlated with 40 disorders or traits-positively with all psychiatric disorders and negatively with BMI, age at first birth and multiple autoimmune diseases. The GWAS meta-analysis identified several biologically informative genes as important contributors to the aetiology of OCD. Overall, we have begun laying the groundwork through which the biology of OCD will be understood and described.
Competing Interest Statement
David A. Hinds and Chao Tian are employed by and hold stock or stock options in 23andMe, Inc. ADB has received speaker fee from Lundbeck. JH has received lecture honoraria as part of continuing medical education programs sponsored by Shire, Takeda and Medice. DMC receives royalties for contributing articles to UpToDate, Wolters Kluwer Health, and personal fees for editorial work from Elsevier, all unrelated to the current work. All other authors report to conlficts of interests.
Funding Statement
The iPSYCH team was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003), NIH/NIMH (1R01MH124851-01 to A.D.B.) and the Universities and University Hospitals of Aarhus and Copenhagen. The Danish National Biobank resource was supported by the Novo Nordisk Foundation. High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus University, Denmark (grant to A.D.B.). A.D.B. was also supported by the EU's HORIZON-HLTH-2021-STAYHLTH-01programme, project number 101057385: Risk and Resilience in Developmental Diversity and Mental Health (R2D2-MH). The NORDiC study was supported by NIH grant R01MH110427 (PI: Crowley), NIMH R01 MH105500 (PI Crowley); the Swedish Research Council (grant numbers 2015-02271, 2018-02487) (PIs: Mataix-Cols and Rueck), CIMED and Region Stockholm (PI: Rueck). The computation was performed on resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) under Project sens2018605.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Individual studies obtained ethical approvals from their local IRB / oversight body: The OCGAS study was approved by the Hopkins Medicine Institutional Review Boards, the Butler Institutional Review Board, the UCLA Institutional Review Boards, the Mass General Brigham Human Research Committee, the Columbia University Institutional Review Boards, and the National Institutes of Health Institutional Review Board (NIH IRB). The IOCDF-GC study (comprising of IOCDF-GC and -trio) was approved by the relevant IRBs at all participating sites. This includes the local IRBs in Bonn, Germany, and Capetown, South Africa. Overall IRB was obtained from the the Mass General Brigham Human Research Committee (which includes the use of controls obtained through the dbGaP repository). The NORDiC-SWE study was approved by the Regional Ethics Committee, Stockholm (EPN Stockholm) and the Institutional Review Board (IRB) at the University of North Carolina at Chapel Hill. The NORDiC-NOR study was approved by the Norwegian Regional Committee for Medical and Health Research Ethics (REC-West) under project number 2018/52 REKVest (PI Bjarne Hansen) and project number: 2014/75 REKVest (PI: Jan Haavik). The iPSYCH study was approved by the Regional Scientific Ethics Committee in Denmark and the Danish Data Protection Agency. Participants provided informed consent and participated in the research online, under a protocol approved by the external AAHRPP-accredited IRB, Ethical Independent Review Services (EIReview). Participants were included in the analysis on the basis of consent status as checked at the time data analyses were initiated.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
2
Blogs/Media
Author Videos